her2
Advertisement
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer.
The phase II MAINTAIN trial evaluated the efficacy of adding ribociclib to endocrine therapy in patients with hormone ...
In the phase II SYSUCC-005 trial, researchers explored the effectiveness of switching treatment modalities after ...
The U.S. Food and Drug Administration granted accelerated approval to Enhertu® (fam-trastuzumab deruxtecan-nxki) for ...
Trastuzumab deruxtecan demonstrated durable anti-tumor activity in previously treated patients with human epidermal ...
The investigational bispecific T-cell engager (BiTE) PRS-343 was well tolerated and demonstrated anti-tumor activity in ...
A group of researchers has recently identified several genetic mutations associated with severe breast cancer. This ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.